The level of nonclassical monocytes was significantly increased and selectively suppressed by GC in patients with NMO.
Circulating nonclassical monocytes, the levels of IL-1β and TNF-α are all correlated with NMO disability severity.
Nonclassical monocytes may be a potential disease biomarker and a therapeutic target in the active phase of NMO.